Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer

Episode 335: Novel immune therapies for renal cancer

Episodio 334 en español: Tres Uramigas ASCO 2024

Episode 333: The Uromigos Cup - The Netherlands

Episode 332: The Uromigos Cup - Germany's Entry

Episode 331: AUA 2024 NMIBC Highlights

Episode 330: ASCO 2024 Highlights

Episode 329: Japan in the Uromigos Cup qualifying round

Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies

Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates

Episode 326 ASCO24: KIM-1 in Renal Cancer

Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer

Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC

Episode 323 ASCO24: TDXD in Bladder Cancer

Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)

Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

Episode 320: Team Canada's entry for the Uromigos Cup

Episode 319: ASCO 2024: A Preview of GU Data

Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases

Episode 317: AUA 2024 Preview with the AUA Secretary